Zobrazeno 1 - 10 of 21 pro vyhledávání: '"Christina, Schlecker"'
1
Akademický článek
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
Autor: Toby M Maher, Michael Kreuter, Vincent Cottin, Daniel Wachtlin, Anna-Maria Hoffmann-Vold, Marlies S Wijsenbeek, Fernando J Martinez, Shervin Assassi, Luca Richeldi, Arata Azuma, Justin M Oldham, Claudia Valenzuela, Carl Coeck, Christina Schlecker, Florian Voss
Publikováno v: BMJ Open Respiratory Research, Vol 10, Iss 1 (2023)
Introduction Progressive pulmonary fibrosis (PPF) includes any diagnosis of progressive fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). However, disease progression appears comparable between PPF and IPF, sugg
Externí odkaz: https://doaj.org/article/0431457e10d0437986592042ea5048ab
Zobrazit plný text záznamu
2
Akademický článek
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
Autor: Toby M. Maher, Christina Schlecker, Doreen Luedtke, Sebastian Bossert, Donald F. Zoz, Armin Schultz
Publikováno v: ERJ Open Research, Vol 8, Iss 4 (2022)
Introduction BI 1015550 is a phosphodiesterase 4 (PDE4) inhibitor that has antifibrotic properties. Phase I and Ic studies were conducted to investigate the safety, tolerability and pharmacokinetics of BI 1015550 in healthy male subjects and patients
Externí odkaz: https://doaj.org/article/21b9b0816508498c90339a882a036afe
Zobrazit plný text záznamu
6
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
Autor: Toby M, Maher, Christina, Schlecker, Doreen, Luedtke, Sebastian, Bossert, Donald F, Zoz, Armin, Schultz
IntroductionBI 1015550 is a phosphodiesterase 4 (PDE4) inhibitor that has antifibrotic properties. Phase I and Ic studies were conducted to investigate the safety, tolerability and pharmacokinetics of BI 1015550 in healthy male subjects and patients
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cc33ee0552be7587e3a47357d3f4ec9
http://hdl.handle.net/10044/1/100466
Zobrazit plný text záznamu
8
Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies
Autor: Michael Desch, Bernhard Schmid, Riccardo Giovannini, Viktoria Moschetti, Glen Wunderlich, Christina Schlecker, Karl-Heinz Liesenfeld, Sascha Keller, Sophia Goetz, Cornelia Dorner-Ciossek, Sven Wind, Oliver Kleiner, Steven Ramael, Gwenaëlle Fillon, Holger Rosenbrock
Publikováno v: Clinical and Translational Science
BI 425809 is a potent and selective glycine transporter 1 (GlyT1) inhibitor being developed for the treatment of cognitive impairment in Alzheimer disease and schizophrenia. Translational studies evaluated the effects of BI 425809 on glycine levels i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feadccd75c538a282afb4f73b40a0f02
https://doi.org/10.1111/cts.12578
Zobrazit plný text záznamu
9
Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics
Autor: Armin Schultz, Sophia Goetz, Karl-Heinz Liesenfeld, Christina Schlecker, Michael Desch, Holger Schmitt, Viktoria Moschetti, Glen Wunderlich, Sven Wind
Publikováno v: Clinical Drug Investigation
Background and Objective Schizophrenia and Alzheimer’s disease are characterised by abnormalities in glutamatergic pathways related to N-methyl-d-aspartate receptor hypofunction. Glycine is an N-methyl-d-aspartate receptor co-agonist; inhibition of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff2ecf545edb1ee14c2574ef5ab68c9
https://doi.org/10.1007/s40261-018-0660-2
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje